EP4724433A2 - Médicaments psychoactifs et leur utilisation pour le traitement de pathologies et de troubles psychiatriques et neurologiques - Google Patents
Médicaments psychoactifs et leur utilisation pour le traitement de pathologies et de troubles psychiatriques et neurologiquesInfo
- Publication number
- EP4724433A2 EP4724433A2 EP24819953.1A EP24819953A EP4724433A2 EP 4724433 A2 EP4724433 A2 EP 4724433A2 EP 24819953 A EP24819953 A EP 24819953A EP 4724433 A2 EP4724433 A2 EP 4724433A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- methylone
- subject
- disorder
- neuropsychiatric illness
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des médicaments psychoactifs comprenant du méthylone, du 2C-B, de la MBDB, leurs sels, métabolites, isomères, énantiomères, solvates, isotopologues et isotopomères, polymorphes, promédicaments et analogues respectifs (série 2C et cathinones) ; leur préparation, leurs formulations, leurs intermédiaires, leurs voies d'administration, leur dosage et leur calendrier destinés à des usages médicaux pour des pathologies et des troubles psychiatriques et neurologiques.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363471412P | 2023-06-06 | 2023-06-06 | |
| US202363602904P | 2023-11-27 | 2023-11-27 | |
| US202363605729P | 2023-12-04 | 2023-12-04 | |
| US202363607702P | 2023-12-08 | 2023-12-08 | |
| US202463553788P | 2024-02-15 | 2024-02-15 | |
| US202463649653P | 2024-05-20 | 2024-05-20 | |
| PCT/US2024/032615 WO2024254190A2 (fr) | 2023-06-06 | 2024-06-05 | Médicaments psychoactifs et leur utilisation pour le traitement de pathologies et de troubles psychiatriques et neurologiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4724433A2 true EP4724433A2 (fr) | 2026-04-15 |
Family
ID=98099691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24819953.1A Pending EP4724433A2 (fr) | 2023-06-06 | 2024-06-05 | Médicaments psychoactifs et leur utilisation pour le traitement de pathologies et de troubles psychiatriques et neurologiques |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4724433A2 (fr) |
| AU (1) | AU2024284688A1 (fr) |
| IL (1) | IL324918A (fr) |
| MX (1) | MX2025014366A (fr) |
-
2024
- 2024-06-05 MX MX2025014366A patent/MX2025014366A/es unknown
- 2024-06-05 IL IL324918A patent/IL324918A/en unknown
- 2024-06-05 AU AU2024284688A patent/AU2024284688A1/en active Pending
- 2024-06-05 EP EP24819953.1A patent/EP4724433A2/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL324918A (en) | 2026-01-01 |
| AU2024284688A1 (en) | 2025-12-11 |
| MX2025014366A (es) | 2026-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025036702A (ja) | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 | |
| US11969407B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| TWI553006B (zh) | 依託拉嗪(eltoprazine)於治療與神經或心理疾病有關之認知失能之症狀的用途 | |
| TW202306571A (zh) | 確定待投與於個體的致幻劑之劑量或與另一種致幻劑之劑量等效性之方法 | |
| US20220265582A1 (en) | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy | |
| WO2023191952A1 (fr) | Médicaments psychoactifs et leur utilisation pour le traitement de pathologies et de troubles psychiatriques et neurologiques | |
| US12343326B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US12295937B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US20250332139A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| WO2024254190A2 (fr) | Médicaments psychoactifs et leur utilisation pour le traitement de pathologies et de troubles psychiatriques et neurologiques | |
| AU2024284688A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US20250221957A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| KR20260053276A (ko) | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 | |
| HK40120411A (zh) | 精神作用药物及其用於治疗精神和神经病状和病症的用途 | |
| HK40112015A (zh) | 精神作用药物及其用於治疗精神和神经病状和病症的用途 | |
| CN118434416A (zh) | 精神作用药物及其用于治疗精神和神经病状和病症的用途 | |
| HK40068315A (en) | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20260106 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |